zurück

Empagliflozin (new indication: chronic heart failure)


Subject:

  • Active Substance: Empagliflozin
  • Name: Jardiance®
  • Therapeutic area: Heart failure
  • Pharmaceutical company: Boehringer Ingelheim Pharma GmbH & Co. KG


Time table:

  • Start: 01.04.2022
  • Final decision by G-BA: 15.09.2022


Final decision:

  • HInt for a minor additional benefit